Literature DB >> 4052287

Myocardial infarct size and mortality in diabetic patients.

D J Gwilt, M Petri, P W Lewis, M Nattrass, B L Pentecost.   

Abstract

The mortality rate from myocardial infarction is disproportionately high in diabetic patients. One explanation for this may be that diabetic patients incur more extensive myocardial necrosis. This possibility was examined in a three part study. Firstly, peak serum aspartate aminotransferase concentrations of all diabetic and non-diabetic patients admitted with myocardial infarction over a 16 year period were compared retrospectively. Secondly, peak aspartate aminotransferase concentrations in a series of diabetic patients and controls matched by age and sex were examined retrospectively. Thirdly, creatine kinase MB release and electrocardiographic measures of infarct size were investigated prospectively in a case/control study. Although cardiac failure and death were more common in the diabetic groups, there were no significant differences in estimates of infarct size between diabetic and non-diabetic patients in any of the studies. Therefore, the high case fatality rate amongst diabetic patients is not caused by increased myocardial damage. Presumably survival is prejudiced by factors operating before the infarction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4052287      PMCID: PMC481931          DOI: 10.1136/hrt.54.5.466

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  27 in total

1.  Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

Authors:  M J Garcia; P M McNamara; T Gordon; W B Kannel
Journal:  Diabetes       Date:  1974-02       Impact factor: 9.461

2.  Coronary care for myocardial infarction in diabetics.

Authors:  N G Soler; B L Pentecost; M A Bennett; M G FitzGerald; P Lamb; J M Malins
Journal:  Lancet       Date:  1974-03-23       Impact factor: 79.321

3.  Estimation of infarct size in man and its relation to prognosis.

Authors:  B E Sobel; G F Bresnahan; W E Shell; R D Yoder
Journal:  Circulation       Date:  1972-10       Impact factor: 29.690

4.  Intravenous glucose tolerance, insulin, glucose, and free fatty acid levels after myocardial infarction.

Authors:  S P Allison; M J Chamberlain; P Hinton
Journal:  Br Med J       Date:  1969-12-27

5.  Factors associated with long-term survival of diabetics.

Authors:  S Pell; C A D'Alonzo
Journal:  JAMA       Date:  1970-12-07       Impact factor: 56.272

6.  Observations on the diagnostic and prognostic value of some enzyme tests in myocardial infarction.

Authors:  O Kibe; N J Nilsson
Journal:  Acta Med Scand       Date:  1967-11

7.  Clinical measurement of myocardial infarct size. Modification of a method for the estimation of total creatine phosphokinase release after myocardial infarction.

Authors:  R M Norris; R M Whitlock; C Barratt-Boyes; C W Small
Journal:  Circulation       Date:  1975-04       Impact factor: 29.690

8.  Plasma protein changes, blood viscosity, and diabetic microangiopathy.

Authors:  D E McMillan
Journal:  Diabetes       Date:  1976       Impact factor: 9.461

Review 9.  Red cell deformability, platelet aggregation, and insulin action.

Authors:  P Vague; I Juhan
Journal:  Diabetes       Date:  1983-05       Impact factor: 9.461

10.  Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity.

Authors:  W E Shell; J K Kjekshus; B E Sobel
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808

View more
  13 in total

1.  Five-year mortality after acute myocardial infarction in relation to previous history, level of initial care, complications in hospital, and medication at discharge.

Authors:  J Herlitz; A Bång; M Sjölin; B W Karlson
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

2.  Raised concentrations of glucose and adrenaline and increased in vivo platelet activation after myocardial infarction.

Authors:  G A Oswald; C C Smith; A P Delamothe; D J Betteridge; J S Yudkin
Journal:  Br Heart J       Date:  1988-06

Review 3.  How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death?

Authors:  J G Cleland; S Puri
Journal:  Br Heart J       Date:  1994-09

Review 4.  Metabolic abnormalities in the diabetic heart.

Authors:  Gary D Lopaschuk
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

5.  Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants.

Authors:  A K M Tarikuz Zaman; Satoshi Fujii; David J Schneider; Douglas J Taatjes; H Roger Lijnen; Burton E Sobel
Journal:  Histochem Cell Biol       Date:  2007-06-19       Impact factor: 4.304

6.  Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.

Authors:  R P Gray; J S Yudkin; D L Patterson
Journal:  Br Heart J       Date:  1993-03

7.  Elevated glycated haemoglobin in non-diabetic patients is associated with an increased mortality in myocardial infarction.

Authors:  T A Chowdhury; S S Lasker
Journal:  Postgrad Med J       Date:  1998-08       Impact factor: 2.401

Review 8.  Atypical presentation of acute and chronic coronary artery disease in diabetics.

Authors:  Hadi Ar Hadi Khafaji; Jassim M Al Suwaidi
Journal:  World J Cardiol       Date:  2014-08-26

9.  The relationship of hospital admission and fatality from myocardial infarction to glycohaemoglobin levels.

Authors:  J S Yudkin; G A Oswald; P M McKeigue; R D Forrest; C A Jackson
Journal:  Diabetologia       Date:  1988-04       Impact factor: 10.122

10.  Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide.

Authors:  Saisudha Koka; Lei Xi; Rakesh C Kukreja
Journal:  Mol Cell Biochem       Date:  2020-03-11       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.